MK-677
Also called Ibutamoren, Nutrobal, L-163191
Research reference
- Research amount range
- 25–25 mg per administration — not a starting amount
- Reference frequency
- Every day — catalogue input, not a personal schedule
- Evidence route
- Oral in the cited evidence; formulation matters.
- Model accumulation timescale
- ~30 hours — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
MK-677
Evidence gap- When change was measured
- Human exposure or dose research exists for MK-677, but this catalogue has no source-backed window for a visible or functional result. Pharmacokinetic or biomarker timing is not the same as outcome timing.
- When to assess
- No evidence-based reassessment point is available for this catalogue entry. Half-life or clearance time cannot be used as a proxy for when a result should appear.
- Conditions and limitations
- No source-backed special condition—such as fasting, local injection, exercise timing, or a companion compound—has been established for the claimed outcomes. Route and formulation still matter.
- When to stop
- No validated target, maintenance phase, or quit rule is available. Do not extend or increase exposure solely because an expected result has not appeared; a severe or persistent reaction warrants stopping and prompt clinical review.
Sources: Chapman IM et al., JCEM 1996;81:4249
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Combination evidence and cautions
What is known and unknown about MK-677 alongside other compounds or medicines.
Key properties
- Formula
- C27H36N4O5S
- Mol. weight
- 528.7 Da
- CAS
- 159634-47-6
- PubChem CID
- 178024
External references
About 4–6 hours; taken as a once-daily oral capsule.
An orally active growth-hormone secretagogue taken as a once-daily capsule; the 25 mg figure shown is a nominal oral capsule strength, not a vial. The human evidence is oral, so no injected schedule is shown.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.07× single dose
- Time to steady state
- 30hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Chapman IM et al., JCEM 1996;81:4249Daily oral MK-677 25 mg raised growth hormone and IGF-1 in healthy older volunteers over months.